Literature DB >> 11701668

Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration.

M Braga1, M D Ringel, D S Cooper.   

Abstract

Chronic endogenous TSH stimulation of neoplastic tissue has been reported to stimulate tumor enlargement. However, little is known about changes in normal and neoplastic thyroid tissue after sudden rather than chronic stimulation with TSH. Acute thyroidal tissue reactions, reflected by rapid tumor expansion and/or possible vascular changes, have been reported to occur after bovine TSH stimulation and, more recently, after recombinant human TSH (rhTSH). In this report, we describe two patients with papillary thyroid carcinoma with local recurrent tumor. Both patients developed tumor growth 12-48 h after the second rhTSH injection, reflected by acute respiratory distress or a palpable, tender mass. In both situations, the enlargement was documented by imaging techniques, showing tumor expansion compared with previous examinations. Rapid improvement with glucocorticoid supports inflammation as the likely etiology. Based on these cases, and other reports of rapid tumor expansion after rhTSH injection, we recommend glucocorticoid coverage before rhTSH administration for patients with known or suspected neoplasia located in a limited space.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701668     DOI: 10.1210/jcem.86.11.8055

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

2.  What role for recombinant human TSH in the treatment of metastatic thyroid cancer?

Authors:  Paolo Zanotti-Fregonara; Elif Hindié; Marie Elisabeth Toubert; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer.

Authors:  M Ralli; P Cohan; K Lee
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

5.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 6.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

7.  Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.

Authors:  Megan Rist Haymart; Daniel John Repplinger; Glen E Leverson; Diane F Elson; Rebecca S Sippel; Juan Carlos Jaume; Herbert Chen
Journal:  J Clin Endocrinol Metab       Date:  2007-12-26       Impact factor: 5.958

8.  Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.

Authors:  Barbara Jarzab; Daria Handkiewicz-Junak; Józef Roskosz; Zbigniew Puch; Zbigniew Wygoda; Aleksandra Kukulska; Beata Jurecka-Lubieniecka; Kornelia Hasse-Lazar; Maria Turska; Aleksander Zajusz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-29       Impact factor: 9.236

Review 9.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

10.  Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration.

Authors:  Seung Hyun Son; Sang-Woo Lee; Ji-Hoon Jung; Choon-Young Kim; Do-Hoon Kim; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.